The USFDA has recently announced certain actions to be taken in response to the ongoing pandemic. The FDA made changes to the authorized use of the monoclonal antibodies bamlanivimab and etesevimab. Additionally, it has issued a letter to veterinarians and retailers about sharing critical information with consumers about the adverse effects of animal ivermectin.
The US Food and Drug Administration has announced a set of actions to be undertaken in response to the ongoing pandemic: On the 27 th of August , the USFDA made changes in the emergency use of two monoclonal antibodies, bamlanivimab and etesevimab . The combined use of these drugs will only be allowed in the states, territories, and US jurisdictions wherein the recent data reveals a combined frequency of variants resistant to these drugs is less than or equal to 5% . The FDA has posted a list of authorized and not authorized…
